Health Care Service Corp. will cease reimbursing for injections of amniotic-tissue products made by MiMedx Group Inc. and other manufacturers, The Wall Street Journal reported.

The insurer said the products, touted as helping with hair loss, erectile dysfunction, knee pain and osteoarthritis, are "experimental, investigational and/or unproven for all indications." The insurer would only cover limited uses for amniotic skin grafts treatments, such as MiMedx's EpiFix allograft, according to the report.

The move took effect Aug. 1.